Circular RNA ZFR accelerates non-small cell lung cancer progression by acting as a miR-101-3p sponge to enhance CUL4B expression
Source abstract
Abstract
BACKGROUND: Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer. Circular RNA ZFR (circZFR) is an identified circular RNA (circRNA) that is correlated with cancer progression. However, the role of circZFR in NSCLC remains unknown. In the present study, we aimed to investigate the function of circZFR in NSCLC and the underlying mechanism. METHODS: hybridization (FISH). Cell proliferation was examined utilizing the CCK-8 assay. Cell migration and invasion were evaluated using the Transwell assay. We used the bioinformatics software TargetScan and miRanda to predict circRNA-miRNA and miRNA-mRNA interactions. RESULTS: . Furthermore, we demonstrated that circZFR acted as a sponge to absorb microRNA-101-3p (miR-101-3p) and promoted cullin 4B (CUL4B) expression. CONCLUSIONS: Collectively, our results demonstrated that circZFR exhibited a carcinogenic role by sponging miR-101-3p and regulating CUL4B expression in NSCLC. These findings provided evidence for understanding the role of circZFR in NSCLC tumourigenesis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Thoracic Surgery, Huaihe Hospital of Henan University
College of Nursing and Health, Henan University
Funding
Key Program of Natural Science Foundation of Henan Provincial Department of Science and Technology in China
References (25)
Show source-provided references
1. 10.1016/j.semcancer.2017.09.00510.1016/j.semcancer.2017.09.005 ↗
2. 10.1016/j.rmed.2010.08.00510.1016/j.rmed.2010.08.005 ↗
3. 10.1093/jjco/hyx14710.1093/jjco/hyx147 ↗
4. PDQ Adult Treatment Editorial Board. Non-small cell lung cancer treatment (PDQ®): patient version. Bethesda (MD): National Cancer Institute; 2002; (PDQ cancer information summaries).
5. 10.5604/01.3001.0010.382610.5604/01.3001.0010.3826 ↗
6. 10.1016/S0140-6736(16)31473-810.1016/S0140-6736(16)31473-8 ↗
7. 10.1016/j.bbagrm.2015.07.00710.1016/j.bbagrm.2015.07.007 ↗
8. 10.1080/15476286.2017.136788610.1080/15476286.2017.1367886 ↗
9. 10.3390/genes812035310.3390/genes8120353 ↗
10. 10.3389/fmolb.2017.0003810.3389/fmolb.2017.00038 ↗
11. 10.1016/j.gde.2017.11.00710.1016/j.gde.2017.11.007 ↗
12. 10.4143/crt.2017.53710.4143/crt.2017.537 ↗
13. 10.1016/j.abb.2018.11.02010.1016/j.abb.2018.11.020 ↗
14. 10.1016/j.bbrc.2018.05.17410.1016/j.bbrc.2018.05.174 ↗
15. 10.1042/BSR2017075010.1042/BSR20170750 ↗
16. 10.1016/j.bbcan.2018.06.00210.1016/j.bbcan.2018.06.002 ↗
17. 10.1016/j.prp.2017.02.01110.1016/j.prp.2017.02.011 ↗
18. 10.1016/j.bbrc.2018.07.07010.1016/j.bbrc.2018.07.070 ↗
19. 10.18632/oncotarget.907210.18632/oncotarget.9072 ↗
20. 10.1007/s11060-018-2973-710.1007/s11060-018-2973-7 ↗
21. 10.18632/oncotarget.2460110.18632/oncotarget.24601 ↗
22. Lu HM, Yi WW, Ma YS, et al. Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer. Oncol Lett. 2018;16:7048–7056.
23. 10.1016/j.biopha.2017.07.00510.1016/j.biopha.2017.07.005 ↗
24. 10.1002/1878-0261.1203810.1002/1878-0261.12038 ↗
25. 10.3727/096504016X1466699034747310.3727/096504016X14666990347473 ↗